Vivace Therapeutics key facts
as of Oct 2026- Operator of a small molecule drug discovery firm intended to introduce new treatments for cancer patients.
- Vivace Therapeutics is valued at approximately $125.0M as of Oct 2026, set at its later-stage round, Feb 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $105.0M across 4 recorded rounds; the latest was Later Stage VC (Series D) ($35.0M) in Feb 2025.
- Notable investors include Sequoia Capital, Hongshan Capital Group, RA Capital Management, Canaan Partners, Mission BioCapital — 11 tracked in total.
- Vivace Therapeutics has filed 5 Form Ds with the SEC since 2015, most recently Mar 2025 ($17.5M sold to 5 investors).
- Status: Privately Held (backing).
Valued at $125.0M at its later-stage round, Feb 2025. Nothing has traded since.
- ·The complete investor list: 11 names
- ·Watch Vivace Therapeutics: the Monday email on marks, rounds and moves
Vivace Therapeutics funding rounds
4 roundsWho backs Vivace Therapeutics
11+Vivace Therapeutics valuation
Vivace Therapeutics was valued at $125 million at its later-stage round in Feb 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Vivace Therapeutics raised?
Vivace Therapeutics has raised $105 million across 4 recorded rounds since 2015. The largest was an $8 million early-stage round in May 2017; the most recent was a $35 million Series D in Feb 2025.
Vivace Therapeutics has filed 5 Form Ds with the SEC since 2015, most recently in Mar 2025 ($17.5 million sold to 5 investors).
Vivace Therapeutics investors
11 investors are on record for Vivace Therapeutics, including Sequoia Capital, Hongshan Capital Group, RA Capital Management and Canaan Partners. The Series D in Feb 2025 drew 2 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Imbria Pharmaceuticals ($132 million), Tahoe ($131 million) and Arsenal Medical ($124 million).
About Vivace Therapeutics
Operator of a small molecule drug discovery firm intended to introduce new treatments for cancer patients. The company creates therapies that target distinct biological pathways and function either alone or alongside existing drugs, enabling healthcare professionals to access additional options for cancers with limited treatment alternatives.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- San Mateo, CA, United States
- Founded
- 2014
- Employees
- 10
- Website
- vivacetherapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.